$4SCAR2.0: a multi-CAR-T therapy regimen for the treatment of relapsed/refractory B cell lymphomas$

4SCAR2.0: a multi-CAR-T therapy regimen for the treatment of relapsed/refractory B cell lymphomas

Bibliographic Details
Main Authors:	Cheng Jiao, Eugene Zvonkov, Xun Lai, Rui Zhang, Yuchen Liu, Yue Qin, Valery Savchenko, Nelly Gabeeva, Tsai-Hua Chung, Liyuan Sheng, Lung-Ji Chang
Format:	Article
Language:	English
Published:	Nature Publishing Group 2021-03-01
Series:	Blood Cancer Journal
Online Access:	https://doi.org/10.1038/s41408-021-00455-x

Similar Items

Gemcitabine and oxaliplatinum: an effective regimen in patients with refractory and relapsing Hodgkin lymphoma
by: Gutierrez A, et al.
Published: (2014-11-01)

GDP versus ESHAP Regimen in Relapsed and/or Refractory Hodgkin lymphoma: A Comparison Study
by: Mani Ramzi, et al.
Published: (2015-03-01)

Correction: GDP versus ESHAP Regimen in Relapsed and/or Refractory Hodgkin lymphoma: A Comparison Study
by: Mani Ramzi, et al.
Published: (2015-10-01)

TREATMENT OF RELAPSE AND REFRACTORY HODGKIN LYMPHOMA
by: E. A. Baryakh
Published: (2017-06-01)

Relapsed and refractory classical Hodgkin lymphoma immunotherapy
by: Kirill Lepik
Published: (2020-10-01)

Treatment of Relapsed and Refractory Hodgkin’s Lymphoma in Children
by: NS Kulichkina, et al.
Published: (2016-01-01)

New agents in relapsed/refractory Hodgkin's lymphoma
by: Irene Biasoli, et al.

The role of tazemetostat in relapsed/refractory follicular lymphoma
by: Gottfried von Keudell, et al.
Published: (2021-05-01)

EAM conditioning regimen followed by autologous hematopoietic Stem Cell Transplantation for relapsed, refractory and high risk lymphomas
by: Mohamed BEKADJA, et al.
Published: (2014-08-01)

Highly Diverse Efficacy of Salvage Treatment Regimens for Relapsed or Refractory Peripheral T-Cell Lymphoma: A Systematic Review.
by: Ya-Ting Yang, et al.
Published: (2016-01-01)

Therapeutic Updates for Relapsed and Refractory Classical Hodgkin Lymphoma
by: Timothy J Voorhees, et al.
Published: (2020-10-01)

THE STANDARD OF CARE IN RELAPSED REFRACTORY CD30+ LYMPHOMA
by: Martin Hutchings
Published: (2014-07-01)

Brentuximab vedotin for relapsed or refractory Hodgkin’s lymphoma
by: Chen R, et al.
Published: (2015-03-01)

Temsirolimus in the treatment of relapsed and/or refractory mantle cell lymphoma
by: S Galimberti, et al.
Published: (2010-06-01)

Salvage chemotherapy for adults with relapsed or refractory lymphoma in Malawi
by: Bongani Kaimila, et al.
Published: (2017-08-01)

Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma
by: Xin Li, et al.
Published: (2018-01-01)

Temsirolimus in the treatment of relapsed or refractory mantle cell lymphoma
by: Nousheen Samad, et al.
Published: (2010-09-01)

IEV (Ifosfamide, Epirubicin, VP16) Regimen as Salvage Therapy for Early Relapsed/Refractory non-Hodgkin/Hodgkin Lymphoma
by: Mohammadali Mashhadi, et al.
Published: (2011-09-01)

IEV (Ifosfamide, Epirubicin, VP16) Regimen as Salvage Therapy for Early Relapsed/Refractory non-Hodgkin/Hodgkin Lymphoma
by: Behrooz Najafi, et al.
Published: (2011-10-01)

Liposomal Vincristine as a Bridge Therapy Prior to CAR-T Therapy in Relapsed and Refractory Diffuse Large B-Cell Lymphoma?
by: Juskaran Chadha, et al.
Published: (2019-04-01)

Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond
by: Christopher T. Su, et al.
Published: (2021-07-01)

Safety and Efficacy of BeEAC as a Conditioning Regimen Prior to Autologous Hematopoietic Stem Cell Transplantation in Relapsed/Refractory Lymphomas
by: VO Sarzhevskii, et al.
Published: (2019-03-01)

Relapsed and/or Refractory Mantle cell Lymphoma: What Role for Temsirolimus?
by: Sebastian Kirschey, et al.
Published: (2012-01-01)

Management of relapsed-refractory diffuse large B cell lymphoma
by: Lalit S Raut, et al.
Published: (2014-01-01)

Brentuximab vedotin in the treatment of relapsed and refractory forms of Hodgkin lymphoma
by: E A Demina
Published: (2016-06-01)

Relapsed and/or Refractory Mantle Cell Lymphoma: What Role for Temsirolimus?
by: Sebastian Kirschey, et al.
Published: (2012-03-01)

Dual Immunotherapy Adds Value in Relapsed/Refractory Hodgkin Lymphoma
by: Simon Hallam
Published: (2018-08-01)

Clinical Options in Relapsed or Refractory Hodgkin Lymphoma: An Updated Review
by: Roberta Fedele, et al.
Published: (2015-01-01)

Profile of belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma
by: Bodiford A, et al.
Published: (2014-10-01)

Management of relapsed/refractory marginal zone lymphoma: focus on ibrutinib
by: Denlinger NM, et al.
Published: (2018-03-01)

Role of brentuximab vedotin in the treatment of relapsed or refractory Hodgkin lymphoma
by: Siddiqi T, et al.
Published: (2014-02-01)

CAR T-cell therapy for a relapsed/refractory acute B-cell lymphoblastic lymphoma patient in the context of Li-Fraumeni syndrome
by: Li Zhu, et al.
Published: (2020-06-01)

Proton Therapy as a Bridging Treatment in CAR T-Cell Therapy for Relapsed and Refractory Large B-Cell Lymphoma: Is There a Role?
by: Omran Saifi, MD, et al.
Published: (2020-06-01)

A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patients
by: Cinzia Pellegrini, et al.
Published: (2016-04-01)

Biomodulatory Treatment Regimen, MEPED, Rescues Relapsed and Refractory Classic Hodgkin’s Disease
by: Florian Lüke, et al.
Published: (2021-06-01)

Sustained Remission of Relapsed or Refractory Mantle Cell Lymphoma After 4-1BB-Based CD19-Directed CAR-T Therapy
by: Yang C, et al.
Published: (2020-11-01)

Current and Future Role of Medical Imaging in Guiding the Management of Patients With Relapsed and Refractory Non-Hodgkin Lymphoma Treated With CAR T-Cell Therapy
by: Laetitia Vercellino, et al.
Published: (2021-05-01)

Novel Therapies for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
by: Leonard Jeff Harris, et al.
Published: (2020-11-01)

Safety and Efficacy of Pralatrexate in the Management of Relapsed or Refractory Peripheral T-cell Lymphoma
by: Annabelle L. Rodd, et al.
Published: (2012-01-01)

The Use of Brentuximab Vedotin in Relapsed/Refractory Hodgkin’s Lymphoma in the Kransnodar Region
by: OD Serdyuk, et al.
Published: (2018-01-01)